Fat loss.

FDA-Approved vs Research Compounds: The Three-Tier Framework for Fat Loss Peptides

The fat loss peptide landscape is uniquely stratified by regulatory status. Two compounds hold explicit FDA approval for chronic weight management: Semaglutide (Wegovy) and Tirzepatide (Zepbound). One compound is in Phase 3 trials (Retatrutide). Three compounds are adjunctive research tools (AOD-9604, Tesamorelin, MOTS-c).

TIER 1 — FDA-Approved for Weight Management: Semaglutide and Tirzepatide

Semaglutide is a GLP-1 receptor agonist with a 7-day half-life enabling once-weekly injection. GLP-1 receptor activation in the hypothalamus and brainstem produces profound appetite suppression, slowing of gastric emptying, and improved satiety. The STEP 1 Phase 3 trial demonstrated 14.9% mean body weight reduction over 68 weeks (PMID: 33567185).

Tirzepatide is a dual GLP-1/GIP receptor agonist. The added GIP receptor activation produces greater metabolic effects. SURMOUNT-1 Phase 3 (n=2,519) demonstrated 20.9% mean body weight reduction at 15mg over 72 weeks (PMID: 35658024). Head-to-head data demonstrates Tirzepatide's superiority versus Semaglutide on weight loss and glycemic control (PMID: 34170647).

TIER 2 — Late-Stage Research: Retatrutide (Phase 3 TRIUMPH Program)

Retatrutide is an investigational triple-receptor agonist targeting GLP-1, GIP, and the glucagon receptor. The glucagon receptor component boosts resting energy expenditure and drives additional lipolysis independent of appetite suppression. Phase 2 (NEJM 2023) demonstrated approximately 24.2% body weight reduction at 48 weeks — surpassing both Tier 1 compounds in magnitude (PMID: 37366315). Phase 3 TRIUMPH program is actively enrolling. Not FDA-approved.

TIER 3 — Adjunctive Research Compounds: AOD-9604, Tesamorelin, MOTS-c

AOD-9604 (hGH Fragment 176-191) selectively activates fat-cell beta-3 adrenergic receptors to stimulate lipolysis without anabolic or diabetogenic GH receptor effects. Research-only; no human RCTs for weight management.

Tesamorelin (FDA-approved as EGRIFTA for HIV-associated lipodystrophy) reduces visceral adipose tissue via GH axis stimulation. Phase 3 trials demonstrate 18% VAT reduction over 26 weeks (PMID: 20554713). Mechanism differs from GLP-1 — does not reduce appetite; promotes lipolysis in visceral fat depots via GH/IGF-1 signaling.

MOTS-c is a mitochondria-derived peptide that enhances AMPK activation and glucose utilization. Preclinical research demonstrates reduction of diet-induced obesity and insulin resistance in mice (PMID: 25738459). No human RCTs.

Clinical Evidence Across the Three Tiers

Semaglutide — STEP 1 (Wilding et al., NEJM 2021)

n=1,961 adults, 68 weeks, 14.9% mean body weight reduction vs 2.4% placebo. 86.4% achieved ≥5% weight loss. Prior to GLP-1 agonists, best non-surgical weight loss agents produced 3-5% over comparable timeframes (PMID: 33567185). The SELECT trial subsequently demonstrated 20% reduction in major adverse cardiovascular events.

Tirzepatide — SURMOUNT-1 (Jastreboff et al., NEJM 2022)

n=2,519 adults, 72 weeks. 20.9% mean body weight reduction at 15mg. 91% achieved ≥5% weight loss, 57% achieved ≥20% weight loss. SURPASS-2 head-to-head vs Semaglutide demonstrated Tirzepatide superiority on weight loss and HbA1c endpoints (PMID: 35658024; PMID: 34170647).

Retatrutide — Phase 2 (Jastreboff et al., NEJM 2023)

n=338 participants across multiple dose cohorts. Approximately 24.2% body weight reduction at 48 weeks at the highest dose tested — with the weight loss curve still declining at trial end (PMID: 37366315). If Phase 3 confirms this magnitude, Retatrutide will achieve pharmacological weight loss comparable to bariatric surgery.

Tesamorelin — Phase 3 Pooled Analysis (Falutz et al., JCEM 2010)

Pooled Phase 3 data from HIV-associated lipodystrophy trials demonstrates 18% VAT reduction at 26 weeks. Lean mass and subcutaneous fat preserved. The VAT-selective mechanism is the distinguishing feature versus GLP-1 agonists, which reduce both visceral and subcutaneous fat alongside lean mass (PMID: 20554713).

MOTS-c — Cell Metabolism 2015

Lee et al. characterized MOTS-c as the first mitochondria-encoded peptide regulating systemic metabolism. In mice, MOTS-c reduced diet-induced obesity and insulin resistance by activating AMPK and promoting skeletal muscle glucose utilization (PMID: 25738459). Human RCT data is absent.

Tracking Fat Loss Peptide Outcomes: Research-Appropriate Biomarkers

• Body Weight (% from Baseline): The primary endpoint used in all GLP-1 Phase 3 trials. Measure weekly, standardized (morning, fasted, post-void, same scale). Report as % change from baseline to compare against trial benchmarks. Target: ≥5% at 12 weeks confirms response; ≥15% at 24-36 weeks is achievable with Tirzepatide at therapeutic doses.
• Waist Circumference: Primary proxy for visceral fat. For Tesamorelin protocols (Tier 3), waist circumference is the canonical outcome measure from Phase 3 trials. Disproportionate waist reduction vs total weight change indicates preferential visceral fat mobilization.
• DEXA Body Composition: Distinguishes fat mass from lean mass loss — critical for GLP-1 protocols, which reduce both. A protein-sufficient Semaglutide protocol should show 85-90%+ of weight loss from fat mass. Run at baseline, month 3, month 6.
• Fasting Glucose and HbA1c: GLP-1 agonists improve insulin sensitivity independent of weight loss. Monitor monthly fasting glucose and quarterly HbA1c — provides safety data and confirms GLP-1 pathway engagement. Critical for participants with pre-diabetes or metabolic syndrome.
• Serum IGF-1 (Tesamorelin only): Confirms GH axis engagement. Target: upper-normal range for age. Monitor monthly.

Alternative Stacks and Strategic Considerations

Lifestyle Baseline (All Tiers)

STEP and SURMOUNT trial participants were on calorie-reduced diets with increased activity throughout. The 14.9% and 20.9% weight losses are additive to lifestyle — not standalone drug effects. Any fat loss protocol requires protein-sufficient diet (≥1.6g/kg body weight) and resistance training to minimize lean mass loss.

GLP-1 for Primary Fat Loss (Maximum Magnitude)

For maximum absolute weight reduction, Tirzepatide 15mg is the highest-evidence approach. Tradeoff: 10-15% of total weight loss is lean mass without resistance training. Acceptable for individuals with obesity; sub-optimal for athletes prioritizing body composition.

GH Axis + GLP-1 for Recomposition

For simultaneous fat loss + lean mass preservation, combining a GLP-1 protocol with Tesamorelin + Ipamorelin provides complementary mechanisms: GLP-1 drives appetite suppression; GH axis stimulation selectively mobilizes visceral fat while preserving lean mass. Tradeoff: More complex, higher cost, requires monitoring both GLP-1 tolerance and IGF-1. → See peptidex.app/best/body-recomposition for the dedicated recomposition framework.